(26 March 2009, Cambridge, UK) Linguamatics Ltd, a leader in enterprise text mining for the life science and other markets, today announced that Novo Nordisk, a world-leader in diabetes care, has entered into a multi-year agreement to use the I2E semantic knowledge discovery platform for text mining. At Novo Nordisk I2E will be used to mine published literature and internal information sources to provide business critical intelligence for R&D decision makers. Financial details of the agreement were not disclosed.
I2E's natural language processing (NLP) based text mining delivers relevant, high quality and current insights from content such as biomedical literature, internal reports, patents and news sources to inform business decisions. It is used for a wide variety of life science applications including biomarker discovery, target selection, safety/tox, pharmacogenomics, systems biology, competitor intelligence and sentiment analysis.
"Deriving high value, up-to-date intelligence from unstructured textual data enables Novo Nordisk to make better-informed project decisions," said Henning Nielsen, Director, Library and Information Centre at Novo Nordisk. "We recognize the value that the right text mining tool can provide, and have chosen I2E for its flexibility and range of capabilities including NLP."
"We are pleased to be working with Novo Nordisk who are an established leader in diabetes and hormone therapies," commented Roger Hale, COO and Co-founder of Linguamatics. "I2E's flexibility means that it can deliver value for questions ranging from R&D to business and competitor intelligence."
ABOUT LINGUAMATICS LTD
Linguamatics helps organizations to maximize the value derived from information resources through effective deployment of innovative natural language processing (NLP) based technology. The versatile interactive information extraction system, I2E, helps organizations to do much more than simply cope with vast quantities of information. Its unique combination of search and text mining helps organizations to turn this information into a competitive advantage. From life sciences and healthcare to business intelligence, from media analysis to security, users mine large collections of documents, extracting relevant facts, relationships and quantitative data from content such as scientific papers, news feeds, patents, or internal reports. Linguamatics has a rapidly growing user community with I2E deployed at most top-10 pharma companies. The company was founded in 2001, and is based in Cambridge, UK. For further information on Linguamatics products and solutions, visit www.linguamatics.com.
ABOUT NOVO NORDISK
Novo Nordisk is a healthcare company and a world leader in diabetes care. In addition, Novo Nordisk has a leading position within areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society. With headquarters in Denmark, Novo Nordisk employs approximately 26,000 employees in 79 countries, and markets its products in 180 countries. Novo Nordisk’s B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol ‘NVO’.
The Linguamatics logo is a trademark of Linguamatics Ltd. All rights reserved. All other trademarks mentioned in this document are the property of their respective owners.
For further information please contact:
Tel: +44 (0)7912 944385